Type 2 diabetes mellitus in rheumatoid arthritis and systemic lupus erythematosus: A review

Cover Page

Cite item

Full Text

Abstract

Immunoinflammatory rheumatic diseases (IIRD), such as rheumatoid arthritis and systemic lupus erythematosus, are characterized by common mechanisms of development and similar comorbid pathology, including diabetes mellitus (DM) type 2. Patients with IIRD with concomitant DM represent one of the most difficult groups to manage due to serious complications and forced polypharmacy. The article considers risk factors for carbohydrate metabolism disorders, both traditional and directly associated with rheumatoid arthritis and systemic lupus erythematosus, including the effect of anti-inflammatory therapy on insulin resistance, the risk of DM type 2 and glycemic control, as well as positive pleiotropic properties of some hypoglycemic drugs for the treatment of IIRD, and shows the prospects for further clinical research in this area.

About the authors

Liubov V. Kondratyeva

Nasonova Research Institute of Rheumatology

Author for correspondence.
Email: kondratyeva.liubov@yandex.ru
ORCID iD: 0000-0003-1147-5936

канд. мед. наук, ст. науч. сотр. лаб. системной красной волчанки

Russian Federation, Moscow

Tatiana V. Popkova

Nasonova Research Institute of Rheumatology

Email: kondratyeva.liubov@yandex.ru
ORCID iD: 0000-0001-5793-4689

д-р мед. наук, нач. отд. системных ревматических заболеваний

Russian Federation, Moscow

Evgeny L. Nasonov

Nasonova Research Institute of Rheumatology; Sechenov First Moscow State Medical University (Sechenov University)

Email: kondratyeva.liubov@yandex.ru
ORCID iD: 0000-0002-1598-8360

акад. РАН, д-р мед. наук, проф., науч. рук., зав. каф. ревматологии

Russian Federation, Moscow; Moscow

References

  1. Насонов Е.Л. Проблемы аутоиммунитета в ревматологии. Терапевтический архив. 2023;95(12):1056-03 [Nasonov EL. Autoimmunity in rheumatology: A review. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(12):1056-103 (in Russian)]. doi: 10.26442/00403660.2023.12.202501
  2. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Сахарный диабет 2 типа у взрослых. Сахарный диабет. 2021;23(2S):4-102 [Dedov II, Shestakova MV, Mayorov AY, et al. Diabetes mellitus type 2 in adults. Diabetes Mellitus. 2021;23(2S):4-102 (in Russian)]. doi: 10.14341/dm12507
  3. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104-12 [Dedov II, Shestakova MV, Galstyan GR. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellitus. 2016;19(2):104-12 (in Russian)]. doi: 10.14341/dm2004116-17
  4. Гордеев А.В., Галушко Е.А., Савушкина Н.М., и др. Оценка мультиморбидного профиля (CIRS) при ревматоидном артрите. Первые результаты. Современная ревматология. 2019;13(3):10-6 [Gordeev AV, Galushko EA, Savushkina NM, et al. Assessing the multimorbid profile (CIRS) in rheumatoid arthritis. First results. Modern Rheumatology Journal. 2019;13(3):10-6 (in Russian)]. doi: 10.14412/1996-7012-2019-3-10-16
  5. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62-8. doi: 10.1136/annrheumdis-2013-204223
  6. Cacciapaglia F, Spinelli FR, Bartoloni E, et al. Clinical Features of Diabetes Mellitus on Rheumatoid Arthritis: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group. J Clin Med. 2023;12(6):2148. doi: 10.3390/jcm12062148
  7. Pappas DA, Nyberg F, Kremer JM, et al. Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study. Clin Rheumatol. 2018;37(9):2331-30. doi: 10.1007/s10067-018-4113-3
  8. Асеева Е.А., Соловьев С.К., Клюквина Н.Г., и др. Необратимые органные повреждения в когорте пациентов с системной красной волчанкой (РЕНЕССАНС). Научно-практическая ревматология. 2016;54(4):404-11 [Aseeva EA, Solovyev SK, Klyukvina NG, et al. Irreversible organ damages in a cohort of patients with systemic lupus erythematosus (RENAISSANCE). Rheumatology Science and Practice. 2016;54(4):404-11 (in Russian)]. doi: 10.14412/1995-4484-2016-404-411
  9. Muñoz C, Isenberg DA. Review of major endocrine abnormalities in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2019;37(5):791-9.
  10. Dregan A, Chowienczyk P, Molokhia M. Cardiovascular and type 2 diabetes morbidity and all-cause mortality among diverse chronic inflammatory disorders. Heart. 2017;103(23):1867-83. doi: 10.1136/heartjnl-2017-311214
  11. Tselios K, Gladman DD, Su J, et al. Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus: A Longterm Prospective Study. J Rheumatol. 2017;44(12):1841-89. doi: 10.3899/jrheum.161121
  12. Fernández-Garcés M, Haro G, Micó ML. Predisposing factors to nonfatal cardiovascular events in women with systemic lupus erythematosus. An observational, cross-sectional, multicenter study in Spain from the risk/systemic lupus erythematosus thematic network. Medicine (Baltimore). 2019;98(43):e17489. doi: 10.1097/MD.0000000000017489
  13. Liu S, Si S, Li J, et al. Association between type 1 diabetes and systemic lupus erythematosus: a Mendelian randomization study. Clin Rheumatol. 2024;43(1):41-8. doi: 10.1007/s10067-023-06800-8
  14. Xie W, Jiang H, Chen Y, et al. Relationship between type 1 diabetes and autoimmune diseases in European populations: A two-sample Mendelian randomization study. Front Genet. 2024;15:1335839. doi: 10.3389/fgene.2024.1335839
  15. Liao KP, Gunnarsson M, Källberg H, et al. Specific association of type 1 diabetes mellitus with anti-cyclic citrullinated peptide-positive rheumatoid arthritis. Arthritis Rheum. 2009;60(3):653-60. doi: 10.1002/art.24362
  16. Jiang P, Li H, Li X. Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis. Clin Exp Rheumatol. 2015;33(1):115-21.
  17. Tian Z, Mclaughlin J, Verma A, et al. The relationship between rheumatoid arthritis and diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Endocrinol Metab. 2021;10(2):125-31. doi: 10.1097/XCE.0000000000000244
  18. Jin Y, Chen SK, Liu J, Kim SC. Risk of Incident Type 2 Diabetes Mellitus Among Patients With Rheumatoid Arthritis: A Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2020;72(9):1248-326. doi: 10.1002/acr.24343
  19. Bello N, Meyers KJ, Workman J, et al. Cardiovascular events and risk in patients with systemic lupus erythematosus: Systematic literature review and meta-analysis. Lupus. 2023;32(3):325-41. doi: 10.1177/09612033221147471
  20. Etchegaray-Morales I, Mendoza-Pinto C, Munguía-Realpozo P, et al. Risk of diabetes mellitus in systemic lupus erythematosus: systematic review and meta-analysis. Rheumatology (Oxford). 2024;63(8):2047-105. doi: 10.1093/rheumatology/keae204
  21. Кондратьева Л.В., Попкова Т.В. Оценка риска развития сахарного диабета 2-го типа у больных системной красной волчанкой c помощью опросника FINDRISC. Научно-практическая ревматология. 2020;58(5):489-94 [Kondratieva LV, Popkova TV. Type II diabetes mellitus risk assessment using FINDRISC questionnaire in systemic lupus erythematosus patients. Rheumatology Science and Practice. 2020;58(5):489-94 (in Russian)]. doi: 10.47360/1995-4484-2020-489-494
  22. Кондратьева Л.В., Попкова Т.В., Насонов Е.Л. Оценка риска развития сахарного диабета 2-го типа у больных ревматоидным артритом c помощью шкалы FINDRISK. Научно-практическая ревматология. 2017;55(5):504-8 [Kondratyeva LV, Popkova TV, Nasonov EL. Type 2 diabetes mellitus risk assessment using FINDRISC in patients with rheumatoid arthritis. Rheumatology Science and Practice. 2017;55(5):504-8 (in Russian)]. doi: 10.14412/1995-4484-2017-504-508
  23. Ursini F, Russo E, D'Angelo S, et al. Prevalence of Undiagnosed Diabetes in Rheumatoid Arthritis: an OGTT Study. Medicine (Baltimore). 2016;95(7):e2552. doi: 10.1097/MD.0000000000002552
  24. Pei R, Wang J, He P, et al. Risk factors for type 2 diabetes mellitus in Chinese rheumatoid arthritis patients from 2018 to 2022: a real-world, single-center, retrospective study. Front Immunol. 2024;15:1445639. doi: 10.3389/fimmu.2024.1445639
  25. Ruscitti P, Ursini F, Cipriani P, et al. Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: Results from a cross-sectional study. Medicine (Baltimore). 2017;96(34):e7896. doi: 10.1097/MD.0000000000007896
  26. Zhang K, Jia Y, Wang R, et al. Rheumatoid arthritis and the risk of major cardiometabolic diseases: a Mendelian randomization study. Scand J Rheumatol. 2023;52(4):335-41. doi: 10.1080/03009742.2022.2070988
  27. Wong CY, Ma BMY, Zhang D, et al. Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: a systematic review and meta-analysis. Lupus Sci Med. 2024;11(1):e001152. doi: 10.1136/lupus-2024-001152
  28. Wu J, Mackie SL, Pujades-Rodriguez M. Glucocorticoid dose-dependent risk of type 2 diabetes in six immune-mediated inflammatory diseases: a population-based cohort analysis. BMJ Open Diabetes Res Care. 2020;8(1):e001220. doi: 10.1136/bmjdrc-2020-001220
  29. Dubreuil M, Rho YH, Man A, et al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford). 2014;53(2):346-52. doi: 10.1093/rheumatology/ket343
  30. Ruscitti P, Ursini F, Cipriani P, et al. Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. PLoS One. 2017;12(7):e0181203. doi: 10.1371/journal.pone.0181203
  31. van der Pol JA, Allaart CF, Lems W, et al. Prednisone use, disease activity and the occurrence of hyperglycaemia and diabetes in patients with early rheumatoid arthritis: a 10-year subanalysis of the BeSt study. RMD Open. 2024;10(2):e004246. doi: 10.1136/rmdopen-2024-004246
  32. Baker JF, England BR, George M, et al. Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis. Ann Rheum Dis. 2021;80(5):566-72. doi: 10.1136/annrheumdis-2020-219140
  33. Spranger J, Kroke A, Möhlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52(3):812-7. doi: 10.2337/diabetes.52.3.812
  34. Panagiotakos DB, Pitsavos C, Yannakoulia M, et al. The implication of obesity and central fat on markers of chronic inflammation: The ATTICA study. Atherosclerosis. 2005;183(2):308-15. doi: 10.1016/j.atherosclerosis.2005.03.010
  35. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320(3):C375-31. doi: 10.1152/ajpcell.00379.2020
  36. Шварц В. Воспаление жировой ткани. Часть 1. Морфологические и функциональные проявления. Проблемы Эндокринологии. 2014;55(4):44-9 [Shvarts V. Adipose tissue inflammation. Part 1. Morphological and functional manifestations. Problems of Endocrinology. 2014;55(4):44-9 (in Russian)]. doi: 10.14341/probl200955444-49
  37. Alenezi SA, Khan R, Snell L, et al. The Role of NLRP3 Inflammasome in Obesity and PCOS – A Systematic Review and Meta-Analysis. Int J Mol Sci. 2023;24(13):10976. doi: 10.3390/ijms241310976
  38. Lee HM, Kim JJ, Kim HJ, et al. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes. 2013;62(1):194-204. doi: 10.2337/db12-0420
  39. Unamuno X, Gómez-Ambrosi J, Ramírez B, et al. NLRP3 inflammasome blockade reduces adipose tissue inflammation and extracellular matrix remodeling. Cell Mol Immunol. 2021;18(4):1045-107. doi: 10.1038/s41423-019-0296-z
  40. Wu H, Ballantyne CM. Metabolic Inflammation and Insulin Resistance in Obesity. Circ Res. 2020;126(11):1549-54. doi: 10.1161/CIRCRESAHA.119.315896
  41. Wu H, Ballantyne CM. Skeletal muscle inflammation and insulin resistance in obesity. J Clin Invest. 2017;127(1):43-54. doi: 10.1172/JCI88880
  42. Ying W, Fu W, Lee YS, Olefsky JM. The role of macrophages in obesity-associated islet inflammation and β-cell abnormalities. Nat Rev Endocrinol. 2020;16(2):81-90. doi: 10.1038/s41574-019-0286-3
  43. Elahi R, Nazari M, Mohammadi V, et al. IL-17 in type II diabetes mellitus (T2DM) immunopathogenesis and complications; molecular approaches. Mol Immunol. 2024;171:66-76. doi: 10.1016/j.molimm.2024.03.009
  44. Chung CP, Oeser A, Solus JF, et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008;58(7):2105-12. doi: 10.1002/art.23600
  45. Quevedo-Abeledo JC, Sánchez-Pérez H, Tejera-Segura B, et al. Higher Prevalence and Degree of Insulin Resistance in Patients With Rheumatoid Arthritis Than in Patients With Systemic Lupus Erythematosus. J Rheumatol. 2021;48(3):339-47. doi: 10.3899/jrheum.200435
  46. Solus JF, Chung CP, Oeser A, et al. Genetics of serum concentration of IL-6 and TNFα in systemic lupus erythematosus and rheumatoid arthritis: a candidate gene analysis. Clin Rheumatol. 2015;34(8):1375-82. doi: 10.1007/s10067-015-2881-6
  47. Richter P, Macovei LA, Mihai IR, et al. Cytokines in Systemic Lupus Erythematosus-Focus on TNF-α and IL-17. Int J Mol Sci. 2023;24(19):14413. doi: 10.3390/ijms241914413
  48. Насонов Е.Л., Лила А.М. Ингибиция интерлейкина 6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017;55(6):590-9 [Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):590-9 (in Russian)]. doi: 10.14412/1995-4484-2017-590-599
  49. Аршинов А.В., Левшин Н.Ю., Маслова И.Г., и др. Оценка лабораторных показателей воспаления, инфекции и признаков субклинического атеросклероза у больных системной красной волчанкой. Научно-практическая ревматология. 2024;62(6):633-3 [Arshinov AV, Levshin NY, Maslova IG, et al. Assessment of laboratory indicators of inflammatory, infection and indicators of subclinical atherosclerosis in patients with systemic lupus erythematosus. Rheumatology Science and Practice. 2024;62(6):633-3 (in Russian)]. doi: 10.47360/1995-4484-2024-633-639
  50. Насонов Е.Л., Авдеева А.С., Коротаева Т.В., и др. Роль интерлейкина 17 в патогенезе ревматоидного артрита. Есть ли перспективы применения ингибиторов ИЛ-17? Научно-практическая ревматология. 2023;61(2):165-80 [Nasonov EL, Avdeeva AS, Korotaeva TV, et al. The role of interleukin 17 in the pathogenesis of rheumatoid arthritis. Are there any prospects for the use of IL-17 inhibitors? Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(2):165-80 (in Russian)]. doi: 10.47360/1995-4484-2023-165-180
  51. Лапкина Н.А., Баранов А.А., Речкина О.П., и др. ИЛ-17А, ИЛ-17F и ИЛ-23 у больных ревматоидным артритом. Научно-практическая ревматология. 2024;62(4):402-7 [Lapkina NA, Baranov AA, Rechkina OP, et al. IL-17A, IL-17F and IL-23 in patients with rheumatoid arthritis. Rheumatology Science and Practice. 2024;62(4):402-7 (in Russian)]. doi: 10.47360/1995-4484-2024-402-407
  52. Lim WS, Teoh SE, Tang ASP, et al. The effects of anti-TNF-α biologics on insulin resistance and insulin sensitivity in patients with rheumatoid arthritis: An update systematic review and meta-analysis. Diabetes Metab Syndr. 2024;18(4):103001. doi: 10.1016/j.dsx.2024.103001
  53. Ruscitti P, Ursini F, Cipriani P, et al. IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study. Medicine (Baltimore). 2019;98(7):e14587. doi: 10.1097/MD.0000000000014587
  54. Wang CR, Tsai HW. Immediate-release tofacitinib reduces insulin resistance in non-diabetic active rheumatoid arthritis patients: A single-center retrospective study. World J Diabetes. 2022;13(6):454-65. doi: 10.4239/wjd.v13.i6.454
  55. Di Muzio C, Di Cola I, Shariat Panahi A, et al. The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study. Arthritis Res Ther. 2024;26(1):14. doi: 10.1186/s13075-023-03249-7
  56. Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One. 2010;5(12):e14328. doi: 10.1371/journal.pone.0014328
  57. Chen DY, Chen YM, Hsieh TY, et al. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17(1):52. doi: 10.1186/s13075-015-0559-8
  58. Tournadre A, Pereira B, Dutheil F, et al. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle. 2017;8(4):639-46. doi: 10.1002/jcsm.12189
  59. Toussirot E, Marotte H, Mulleman D, et al. Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study. Arthritis Res Ther. 2020;22(1):224. doi: 10.1186/s13075-020-02297-7
  60. Makrilakis K, Fragiadaki K, Smith J, et al. Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade. Clin Rheumatol. 2015;34(3):419-27. doi: 10.1007/s10067-014-2704-1
  61. van Poppel PC, van Asseldonk EJ, Holst JJ, et al. The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. Diabetes Obes Metab. 2014;16(12):1269-73. doi: 10.1111/dom.12357
  62. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356(15):1517-26. doi: 10.1056/NEJMoa065213
  63. Насонов Е.Л., Авдеева А.С. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;55(4):452-61 [Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type I interferon: new evidence. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(4):452-61 (in Russian)]. doi: 10.14412/1995-4484-2019-452-461
  64. Авдеева А.С., Алексанкин А.П., Четина Е.В., и др. Иммунофенотипы системной красной волчанки – особенности клинических и лабораторных нарушений. Научно-практическая ревматология. 2024;62(4):394-401 [Avdeeva AS, Aleksankin AP, Tchetina EV, et al. Immunophenotypes of systemic lupus erythematosus – features of clinical and laboratory disorders. Rheumatology Science and Practice. 2024;62(4):394-401 (in Russian)]. doi: 10.47360/1995-4484-2024-394-401
  65. Adeva-Andany MM, Carneiro-Freire N, Castro-Quintela E, et al. Interferon Upregulation Associates with Insulin Resistance in Humans. Curr Diabetes Rev. 2025;21(3):86-105. doi: 10.2174/0115733998294022240309105112
  66. Arnaud L, Furie R, Morand EF, et al. Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature. Lupus Sci Med. 2023;10(2):e001032. doi: 10.1136/lupus-2023-001032
  67. Casey KA, Smith MA, Sinibaldi D, et al. Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2021;73(3):459-71. doi: 10.1002/art.41518
  68. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi: 10.1136/ard-2023-224762
  69. Rempenault C, Combe B, Barnetche T, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2018;77(1):98-103. doi: 10.1136/annrheumdis-2017-211836
  70. Li CX, Fan ML, Pang BW, et al. Association between hydroxychloroquine use and risk of diabetes mellitus in systemic lupus erythematosus and rheumatoid arthritis: a UK Biobank-based study. Front Endocrinol (Lausanne). 2024;15:1381321. doi: 10.3389/fendo.2024.1381321
  71. Dima A, Jurcut C, Chasset F, et al. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis. 2022;14:1759720X211073001. doi: 10.1177/1759720X211073001
  72. Giles JT, Danielides S, Szklo M, et al. Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. Arthritis Rheumatol. 2015;67(3):626-36. doi: 10.1002/art.38986
  73. Mirjafari H, Farragher TM, Verstappen SM, et al. Seropositivity is associated with insulin resistance in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register (NOAR): an observational study. Arthritis Res Ther. 2011;13(5):R159. doi: 10.1186/ar3476
  74. Erlandsson MC, Tuameh M, Jukic Huduti E, et al. Clinical Significance of Diabetes-Mellitus-Associated Antibodies in Rheumatoid Arthritis. Cells. 2022;11(22):3676. doi: 10.3390/cells11223676
  75. Cleasby ME, Jamieson PM, Atherton PJ. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J Endocrinol. 2016;229(2):R67-81. doi: 10.1530/JOE-15-0533
  76. Сорокина А.О., Демин Н.В., Добровольская О.В., и др. Патологические фенотипы состава тела у больных ревматическими заболеваниями. Научно-практическая ревматология. 2022;60(4):487-94 [Sorokina AO, Demin NV, Dobrovolskaya OV, et al. Pathological phenotypes of body composition in patients with rheumatic diseases. Rheumatology Science and Practice. 2022;60(4):487-94 (in Russian)]. doi: 10.47360/1995-4484-2022-487-494
  77. Santos MJ, Vinagre F, Canas da Silva J, et al. Body composition phenotypes in systemic lupus erythematosus and rheumatoid arthritis: a comparative study of Caucasian female patients. Clin Exp Rheumatol. 2011;29(3):470-6.
  78. Xie W, Yang X, Ji L, Zhang Z. Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2020;50(4):598-607. doi: 10.1016/j.semarthrit.2020.04.005
  79. Movahedi M, Beauchamp ME, Abrahamowicz M, et al. Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(5):1089-98. doi: 10.1002/art.39537
  80. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. doi: 10.1136/ard-2022-223356
  81. Hoes JN, van der Goes MC, van Raalte DH, et al. Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis. 2011;70(11):1887-94. doi: 10.1136/ard.2011.151464
  82. Sabio JM, Vargas-Hitos JA, Navarrete N, et al. Effects of low or medium-dose of prednisone on insulin resistance in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2010;28(4):483-9.
  83. Baghdadi LR. Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: A systematic review and meta-analysis. PLoS One. 2020;15(7):e0235637. doi: 10.1371/journal.pone.0235637
  84. Nam SH, Kim M, Kim YJ, et al. Risk of New-Onset Diabetes Mellitus Associated with Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Nationwide Population Study. J Clin Med. 2022;11(8):2109. doi: 10.3390/jcm11082109
  85. Su YJ, Chen HM, Chan TM, et al. Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis. RMD Open. 2023;9(3):e003045. doi: 10.1136/rmdopen-2023-003045
  86. Paul SK, Montvida O, Best JH, et al. Association of biological antirheumatic therapy with risk for type 2 diabetes: a retrospective cohort study in incident rheumatoid arthritis. BMJ Open. 2021;11(6):e042246. doi: 10.1136/bmjopen-2020-042246
  87. Ozen G, Pedro S, Holmqvist ME, et al. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. Ann Rheum Dis. 2017;76(5):848-54. doi: 10.1136/annrheumdis-2016-209954
  88. Rekedal LR, Massarotti E, Garg R, et al. Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. Arthritis Rheum. 2010;62(12):3569-73. doi: 10.1002/art.27703
  89. Otsuka Y, Kiyohara C, Kashiwado Y, et al. Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study. PLoS One. 2018;13(4):e0196368. doi: 10.1371/journal.pone.0196368
  90. Gupta-Ganguli M, Cox K, Means B, et al. Does therapy with anti-TNF-alpha improve glucose tolerance and control in patients with type 2 diabetes? Diabetes Care. 2011;34(7):e121. doi: 10.2337/dc10-1334
  91. Ogata A, Morishima A, Hirano T, et al. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis. 2011;70(6):1164-5. doi: 10.1136/ard.2010.132845
  92. Ursini F, Russo E, Letizia Hribal M, et al. Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. Medicine (Baltimore). 2015;94(21):e888. doi: 10.1097/MD.0000000000000888
  93. Martinez-Molina C, Diaz-Torne C, Park HS, et al. Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis. Medicina (Kaunas). 2024;60(3):360. doi: 10.3390/medicina60030360
  94. van Schaik M, Bredewold OW, Priester M, et al. Long-term renal and cardiovascular risks of tacrolimus in patients with lupus nephritis. Nephrol Dial Transplant. 2024;39(12):2048-57. doi: 10.1093/ndt/gfae113
  95. Genovese MC, Burmester GR, Hagino O, et al. Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Res Ther. 2020;22(1):206. doi: 10.1186/s13075-020-02229-5
  96. Kataria Y, Ellervik C, Mandrup-Poulsen T. Treatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients. Semin Immunopathol. 2019;41(4):413-25. doi: 10.1007/s00281-019-00743-6
  97. Ruscitti P, Masedu F, Alvaro S, et al. Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. PLoS Med. 2019;16(9):e1002901. doi: 10.1371/journal.pmed.1002901
  98. Ruscitti P, Berardicurti O, Cipriani P, et al. Benefits of anakinra versus TNF inhibitors in rheumatoid arthritis and type 2 diabetes: long-term findings from participants furtherly followed-up in the TRACK study, a multicentre, open-label, randomised, controlled trial. Clin Exp Rheumatol. 2021;39(2):403-6. doi: 10.55563/clinexprheumatol/phsqg7
  99. Насонов Е.Л., Драпкина О.М. Колхицин: репозиционирование «античного» лекарства в XXI веке. Научно-практическая ревматология. 2024;62(5):445-64 [Nasonov EL, Drapkina OM. Colchicine: Repositioning an “ancient” medicine in the 21st century. Rheumatology Science and Practice. 2024;62(5):445-64 (in Russian)]. doi: 10.47360/1995-4484-2024-445-464
  100. Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One. 2015;10(2):e0117952. doi: 10.1371/journal.pone.0117952
  101. Bartels CM, Saucier JM, Thorpe CT, et al. Monitoring diabetes in patients with and without rheumatoid arthritis: a Medicare study. Arthritis Res Ther. 2012;14(4):R166. doi: 10.1186/ar3915
  102. Hajiesmaeili Y, Tamhankar P, Stranges S, Barra L. Factors associated with incident cardiovascular disease in patients with rheumatoid arthritis: A scoping review. Autoimmun Rev. 2024;23(5):103539. doi: 10.1016/j.autrev.2024.103539
  103. Semb AG, Rollefstad S, Ikdahl E, et al. Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit. RMD Open. 2021;7(2):e001724. doi: 10.1136/rmdopen-2021-001724
  104. Jiang MY, Hwang JC, Feng IJ. Impact of Diabetes Mellitus on the Risk of End-Stage Renal Disease in Patients with Systemic Lupus Erythematosus. Sci Rep. 2018;8(1):6008. doi: 10.1038/s41598-018-24529-2
  105. Hansen RB, Falasinnu T, Faurschou M, et al. Risk of End-Stage Renal Disease in Patients With Systemic Lupus Erythematosus and Diabetes Mellitus: A Danish Nationwide Cohort Study. Arthritis Care Res (Hoboken). 2023;75(9):1871-87. doi: 10.1002/acr.25091
  106. Yuan Q, Xing X, Lu Z, Li X. Clinical characteristics and risk factors of infection in patients with systemic lupus erythematosus: A systematic review and meta-analysis of observational studies. Semin Arthritis Rheum. 2020;50(5):1022-39. doi: 10.1016/j.semarthrit.2020.06.004
  107. Huang JF, Wu QN, Zheng XQ, et al. The Characteristics and Mortality of Osteoporosis, Osteomyelitis, or Rheumatoid Arthritis in the Diabetes Population: A Retrospective Study. Int J Endocrinol. 2020;2020:8821978. doi: 10.1155/2020/8821978
  108. Watanabe R, Ebina K, Gon T, et al. Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study. Rheumatology (Oxford). 2024;63(9):2418-46. doi: 10.1093/rheumatology/keae265
  109. Галушко Е.А., Гордеев А.В., Матьянова Е.В., и др. Труднолечимый ревматоидный артрит в реальной клинической практике. Предварительные результаты. Терапевтический архив. 2022;94(5):661-6 [Galushko EA, Gordeev AV, Matyanova EV, et al. Difficult-to-treat rheumatoid arthritis in real clinical practice. Preliminary results. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(5):661-6 (in Russian)]. doi: 10.26442/00403660.2022.05.201489
  110. Гордеев А.В., Олюнин Ю.А., Галушко Е.А., и др. Труднолечимый ревматоидный артрит. Какой он? Современная ревматология. 2021;15(5):7-11 [Gordeev AV, Olyunin YA, Galushko EA, et al. Difficult-to-treat rheumatoid arthritis. What is it? Modern Rheumatology Journal. 2021;15(5):7-11 (in Russian)]. doi: 10.14412/1996-7012-2021-5-7-11
  111. Насонов Е.Л., Паневин Т.С., Трошина Е.А. Агонисты рецепторов глюкагоноподобного пептида-1: перспективы применения в ревматологии. Научно-практическая ревматология. 2024;62(2):135-44 [Nasonov EL, Panevin TS, Troshina EA. Glucagon-like peptide-1 receptor agonists: Prospects for use in rheumatology. Rheumatology Science and Practice. 2024;62(2):135-44 (in Russian)]. doi: 10.47360/1995-4484-2024-135-144
  112. Du X, Zhang H, Zhang W, et al. The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes. Int Immunopharmacol. 2019;75:105732. doi: 10.1016/j.intimp.2019.105732
  113. Zheng W, Pan H, Wei L, et al. Dulaglutide mitigates inflammatory response in fibroblast-like synoviocytes. Int Immunopharmacol. 2019;74:105649. doi: 10.1016/j.intimp.2019.05.034
  114. Karacabeyli D, Lacaille D. Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis: A Scoping Review. J Clin Rheumatol. 2024;30(1):26-31. doi: 10.1097/RHU.0000000000001949
  115. van Raalte DH, van Genugten RE, Linssen MM, et al. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care. 2011;34(2):412-7. doi: 10.2337/dc10-1677
  116. Gonzalez Moret YA, Lo KB, Tan IJ. Metformin in Systemic Lupus Erythematosus: Investigating Cardiovascular Impact and Nephroprotective Effects in Lupus Nephritis. ACR Open Rheumatol. 2024;6(8):497-503. doi: 10.1002/acr2.11698
  117. Yen FS, Wang SI, Hsu CC, et al. Sodium-Glucose Cotransporter-2 Inhibitors and Nephritis Among Patients With Systemic Lupus Erythematosus. JAMA Netw Open. 2024;7(6):e2416578. doi: 10.1001/jamanetworkopen.2024.16578
  118. Ma KS, Lo JE, Kyttaris VC, et al. Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Cardiovascular, Renal Events, and Safety Outcomes in Patients With Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes: A Population-Based Target Trial Emulation. Arthritis Rheumatol. 2025;77(4):414-22. doi: 10.1002/art.43037
  119. Wagner BR, Rao PS. Sodium-glucose cotransporter 2 inhibitors: are they ready for prime time in the management of lupus nephritis? Curr Opin Rheumatol. 2024;36(3):163-6. doi: 10.1097/BOR.0000000000001002

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».